Number of Participants with Adverse Events of Special Interests (AESIs);Number of Participants with AEs Leading to Study Discontinuation;Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination;Number of Participants with Unsolicited AEs for 28 Days After Vaccination;S Enzyme-linked Immunosorbent Assay (S-ELISA) Geometric Mean Concentrations (GMCs) 28 Days After Vaccination

Number of Participants with Adverse Events of Special Interests (AESIs);Number of Participants with AEs Leading to Study Discontinuation;Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination;Number of Participants with Unsolicited AEs for 28 Days After Vaccination;S Enzyme-linked Immunosorbent Assay (S-ELISA) Geometric Mean Concentrations (GMCs) 28 Days After Vaccination